LATE-BREAKING RESEARCH: CLINICAL/TRANSLATIONAL RESEARCH
Abstract #CT14

Evaluation of the Relationship between Hypoalbuminemia and Oral Anticancer Drug-Related Adverse Events in Adults with Solid Tumor Malignancies

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Adverse Events

Presenter: Jessica Marini, PharmD, PGY2 Oncology Pharmacy Resident, Medical University of South Carolina

Co-Authors: Bailey Bass, Medical University of South Carolina College of Pharmacy; Jacob Rennebaum, Medical University of South Carolina College of Pharmacy; Erin Weeda, Medical University of South Carolina College of Pharmacy; Jagoda Misniakiewicz, Medical University of South Carolina; Amy Sion, Medical University of South Carolina

Background: Tyrosine kinase inhibitors (TKIs) have demonstrated efficacy in multiple solid tumors; however, more than 50% of patients receiving TKI therapy require dose modifications because of adverse events (AEs). TKIs are highly protein-bound drugs, and the presence of hypoalbuminemia may result in increased free-drug concentration, thereby leading to increased drug exposure and AEs.1-8 Because hypoalbuminemia is common among patients with malignancy, we sought to define the relationship between TKI tolerability and low serum albumin levels in adults with solid malignant tumors.

Objective: To evaluate the relationship between hypoalbuminemia and TKI tolerability in adults with solid tumor malignancies.

Methods: This retrospective review included patients who received a highly protein-bound TKI, defined as >95% protein bound, between April 1, 2017, and March 31, 2020, for the management of solid tumors. Patients were excluded if they enrolled in clinical trials or received TKIs for hematologic malignancies. Chart review was conducted to collect baseline characteristics and data for analysis, including, but not limited to, age, weight, baseline albumin, type and stage of cancer at diagnosis, start date of TKI(s) therapy, AEs, albumin at each AE, any adjustments in therapy, date of treatment discontinuation and reason, if applicable. Hypoalbuminemia was defined as serum albumin <3.5 mg/dL.

Results: A total of 220 patients were included for analysis, with 101 patients having hypoalbuminemia at baseline. Patients with hypoalbuminemia had a worse performance status and a higher percentage of baseline liver disease and proteinuria versus patients without these conditions. There was a significantly higher all-cause discontinuation among patients with hypoalbuminemia than those without (83% vs 60%, respectively; P <.001). In addition, the rate of discontinuation because of intolerability was higher in patients with hypoalbuminemia (37% vs 16%, respectively; P <.001). The median time to treatment discontinuation was shorter in those with hypoalbuminemia (4 vs 21 months; P <.001). Hypoalbuminemia was associated with an increased rate of treatment discontinuation after adjusting for covariates (hazard ratio, 2.68; 95% confidence interval, 1.97-3.76). Of the patients who had at least 1 AE, 57% (98/171) had hypoalbuminemia at the time of the event.

Conclusion: Patients with hypoalbuminemia had a significantly higher incidence of AEs leading to earlier discontinuation of TKI therapy. A substantial number of patients who did have AEs had hypoalbuminemia at the time of the AE. Baseline hypoalbuminemia may be an important clinical assessment when initiating TKIs, but further studies are required to establish a relationship between lower starting doses and treatment outcomes.

  1. Liu JW, Chen C, Loh EW, et al. Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2018;34:795-803.
  2. Jackson PR, Tucker GT, Woods HF. Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin. Clin Pharmacol Ther. 1982;32:295-302.
  3. Villarroel MC, Pratz KW, Xu L, et al. Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients. Invest New Drugs. 2012;30:2096-2102.
  4. Gatta A, Verardo A, Bolognesi M. Hypoalbuminemia. Intern Emerg Med. 2012;7(suppl 3):S193-S199.
  5. Nazha B, Moussaly E, Zaarour M, et al. Hypoalbuminemia in colorectal cancer prognosis: nutritional marker or inflammatory surrogate? World J Gastrointest Surg. 2015;7:370-377.
  6. Yoo C, Ryu MH, Ryoo BY, et al. Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. Invest New Drugs. 2012;30:1703-1708.
  7. Drisaldi A, Weeda E, Neyens R, et al. Accuracy of valproic acid concentration correction based on serum albumin. Neurocrit Care. 2019;30:301-306. 
  8. Murdock JL, Duco MR, Reeves DJ. Tolerability of highly protein bound targeted oral oncolytic drugs in patients with hypoalbuminemia: a retrospective analysis. Ann Pharmacother. 2021;55:165-173.
Related Items
Overcoming Resistance: Antibiotic Guidance for Multidrug-Resistant Febrile Neutropenia in Patients with Cancer
Sonya K. Kedzior, PharmD, YoungYoon Ham, PharmD, Joseph Bubalo, PharmD, BCPS, BCOP
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in Review Article, Adverse Events, Antibiotics, Drug Resistance
Welcome to the First Annual Issue of HOPA Abstracts, 2021
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts
Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Patients with Multiple Myeloma Receiving Lenalidomide, Bortezomib, and Dexamethasone
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Multiple Myeloma
Correlation of BRAF Mutation Status in Circulating Tumor DNA with Tumor Biopsy and Clinical Outcomes in the COLUMBUS Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Targeted Therapies
Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Cost of Cancer Management by Stage of Diagnosis Among Medicare Beneficiaries
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Cost of Care
Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600E–Positive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Colorectal Cancer
Incidence of Adverse Effects in Patients with Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Lymphoid Blast Crisis Receiving Ponatinib with or without Concomitant Azole Antifungals
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Leukemia
In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Real-World Dosing Patterns of Ruxolitinib Among Patients with Myelofibrosis: A US Community Oncology Practice
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Oncology Pharmacy Programs, Myelofibrosis
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.